Treatment of epilepsy in daily clinical practice: Have outcomes improved over the past 10 years?

Journal of Neurology

Volumn 260, Issue 11, 2013, Pages 2736-2743

  Wassenaar, Merel ^a,b   Van Heijl, Inger ^c   Leijten, Frans S S ^a   Van Der Linden, Paul ^d   Uijl, Sabine G ^e   Egberts, A C G ^c,e   Carpay, J A ^d,f  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d Tergooi Hospitals   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antiepileptic drugs; Community based; Epilepsy; Quality of life; Treatment outcome

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; ANTICONVULSANT THERAPY; ARTICLE; ATTITUDE TO ILLNESS; CLINICAL PRACTICE; COMMUNITY ASSESSMENT; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE CONTROL; EPILEPSY; FEMALE; HEALTH CARE AVAILABILITY; HEALTH CARE DELIVERY; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NEUROLOGIST; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PRIORITY JOURNAL; QUALITY OF LIFE; SELF REPORT; SUBURBAN AREA; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CHILD; CROSS-SECTIONAL STUDIES; EPILEPSY; FEMALE; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84889606574     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-7058-0     Document Type: Article

References (40)

1. Carpay JA, Aldenkamp AP, van Donselaar CA (2005) Complaints associated with the use of antiepileptic drugs: results from a community-based study. Seizure J Brit Epilep Assoc 14:198-206
2. Sander JW (2004) The use of antiepileptic drugs - principles and practice. Epilepsia 45(Suppl 6):28-34
3. Sander JW (2003) The epidemiology of epilepsy revisited. Curr Opin Neurol 16:165-170
4. Wahab A, Albus K, Gabriel S, Heinemann U (2010) In search of models of pharma co-resistant epilepsy. Epilepsia 51(Suppl 3):154-159
5. Bootsma HP, Ricker L, Hekster YA, Hulsman J, Lambrechts D, Majoie M, Schellekens A, de Krom M, Aldenkamp AP (2009) The impact of side effects on long-term retention in three new antiepileptic drugs. Seizure J Brit Epilep Assoc 18:327-331
6. Helmstaedter C, Schoof K, Rossmann T, Reuner G, Karlmeier A, Kurlemann G (2010) Introduction and first validation of epi track Junior, a screening tool for the assessment of cognitive side effects of antiepileptic medication on attention and executive functions in children and adolescents with epilepsy. Epilep Behav E B 19:55-64
7. Thurman DJ, Beghi E, Begley CE, Berg AT, Buchhalter JR, Ding D, Hesdorffer DC, Hauser WA, Kazis L, Kobau R, Kroner B, Labiner D, Liow K, Logroscino G, Medina MT, Newton CR, Parko K, Paschal A, Preux PM, Sander JW, Selassie A, Theodore W, Tomson T, Wiebe S (2011) Standards for epidemiologic studies and surveillance of epilepsy. Epilepsia 52(Suppl 7):2-26
8. Ross J, Stefan H, Schauble B, Day R, Sander JW (2010) European survey of the level of satisfaction of patients and physicians in the management of epilepsy in general practice. Epilep Behav E B 19:36-42
9. St Louis EK (2010) The art of managing conversions between antiepileptic drugs: maximizing patient tolerability and quality of life. Pharmaceuticals (Basel) 3:2956-2969
10. Kwon OY, Park SP (2011) What is the role of depressive symptoms among other predictors of quality of life in people with well-controlled epilepsy on monotherapy? Epilep Behav E B 20:528-532
11. Luoni C, Bisulli F, Canevini MP, De Sarro G, Fattore C, Galimberti CA, Gatti G, La Neve A, Muscas G, Specchio LM, Striano S, Perucca E (2011) Determinants of health-related quality of life in pharma co-resistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia 52:2181-2191
12. Yue L, Yu PM, Zhao DH, Wu DY, Zhu GX, Wu XY, Hong Z (2011) Determinants of quality of life in people with epilepsy and their gender differences. Epilep Behav E B 22:692-696
13. Taylor J, Jacoby A, Baker GA, Marson AG, Ring A, Whitehead M (2011) Factors predictive of resilience and vulnerability in new-onset epilepsy. Epilepsia 52:610-618
14. Theodore WH, Spencer SS, Wiebe S, Langfitt JT, Ali A, Shafer PO, Berg AT, Vickrey BG (2006) Epilepsy in North America: a report prepared under the auspices of the global campaign against epilepsy, the international bureau for epilepsy, the international league against epilepsy, and the world health organization. Epilepsia 47:1700-1722
15. Loscher W, Schmidt D (2011) Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 52:657-678
16. Brodie MJ, Richens A, Yuen AW, UK Lamotrigine/Carbamazepine Monotherapy Trial Group (1995) Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 345:476-479
17. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA (2004) Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the American academy of neurology and the American epilepsy society. Neurology 62:1252-1260
18. LaRoche SM, Helmers SL (2004) The new antiepileptic drugs: scientific review. JAMA J Am Med Assoc 291:605-614
19. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR (2007) The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369:1016-1026
20. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR (2007) The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369:1000-1015
21. Rowan AJ, Ramsay RE, Collins JF, Pryor F, Boardman KD, Uthman BM, Spitz M, Frederick T, Towne A, Carter GS, Marks W, Felicetta J, Tomyanovich ML (2005) New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 64:1868-1873
22. Hsia Y, Neubert A, Sturkenboom MC, Murray ML, Verhamme KM, Sen F, Giaquinto C, Ceci A, Wong IC (2010) Comparison of antiepileptic drug prescribing in children in three European countries. Epilepsia 51:789-796
23. Perucca P, Jacoby A, Marson AG, Baker GA, Lane S, Benn EK, Thurman DJ, Hauser WA, Gilliam FG, Hesdorffer DC (2011) Adverse antiepileptic drug effects in new-onset seizures: a case-control study. Neurology 76:273-279
24. Shorvon SD (2009) Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009. Epilepsia 50(Suppl 3):93-130
25. Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C (2005) Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Heal Technol Ass 9:1-157
26. Perucca P, Gilliam FG (2012) Adverse effects of antiepileptic drugs. Lan Neurol 11:792-802
27. Uijl SG, Uiterwaal CS, Aldenkamp AP, Carpay JA, Doelman JC, Keizer K, Vecht CJ, de Krom MC, van Donselaar CA (2006) A cross-sectional study of subjective complaints in patients with epilepsy who seem to be well-controlled with anti-epileptic drugs. Seizure Journal Brit Epilep Assoc 15:242-248
28. Cramer JA, Perrine K, Devinsky O, Bryant-Comstock L, Meador K, Hermann B (1998) Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory. Epilepsia 39:81-88
29. Vickrey BG, Perrine KR, Hays RD (1993) Quality of life in epilepsy, QOLIE-31, scoring manual version 1.0. RAND, Santa Monica
30. Groenwold RH, Donders AR, Roes KC, Harrell FE Jr, Moons KG (2012) Dealing with missing outcome data in randomized trials and observational studies. Am J Epidemiol 175:210-217
31. Perucca E (2010) When clinical trials make history: demonstrating efficacy of new antiepileptic drugs as monotherapy. Epilepsia 51:1933-1935
32. Gordon-Perue G, Gayle F, Fraser R, Ali A (2011) Quality of life of patients with epilepsy living in Kingston, Jamaica. Epilep Behavior E B 21:23-26
33. Cramer JA, Steinborn B, Striano P, Hlinkova L, Bergmann A, Bacos I, Baukens C, Buyle S (2011) Non-interventional surveillance study of adverse events in patients with epilepsy. Acta Neurol Scand 124:13-21
34. Kwan P, Yu E, Leung H, Leon T, Mychaskiw MA (2009) Association of subjective anxiety, depression, and sleep disturbance with quality-of-life ratings in adults with epilepsy. Epilepsia 50:1059-1066
35. Taylor RS, Sander JW, Taylor RJ, Baker GA (2011) Predictors of health-related quality of life and costs in adults with epilepsy: a systematic review. Epilepsia 52:2168-2180
36. Panayiotopoulos CP (2007) Evidence-based epileptology, randomized controlled trials, and SANAD: a critical clinical view. Epilepsia 48:1268-1274
37. Kossoff EH (2011) Intractable childhood epilepsy: choosing between the treatments. Semin Pediat Neurol 18:145-149
38. Baker GA, Jacoby A, Buck D, Stalgis C, Monnet D (1997) Quality of life of people with epilepsy: a European study. Epilepsia 38:353-362
39. Kobau R, Zahran H, Thurman DJ, Zack MM, Henry TR, Schachter SC, Price PH (2008) Epilepsy surveillance among adults - 19 States, behavioural risk factor surveillance system, 2005. MMWR Surveill Summ 57:1-20
40. Westerhuis W, Zijlmans M, Fischer K, van Andel J, Leijten FS (2011) Coping style and quality of life in patients with epilepsy: a cross-sectional study. J Neurol 258:37-43